Abstract: A method for measuring and managing DHA levels in a pregnant woman to substantially reduce risk of spontaneous preterm birth, including: determining the blood level of DHA in the pregnant woman at or about the end of the first trimester or beginning of the second trimester, the DHA level being a first comparator; determining level of DHA in at least one pregnant subject at least one predetermined period, where the at least one pregnant subject having achieved a term pregnancy, and where the level of DHA at the at least one predetermined period being at least a second comparator; comparing the level of DHA in the first and at least second comparator; and when the difference between the first and the at least second comparator is greater than a predetermined value, administering to the subject a therapeutically effective amount of DHA to reduce pathology relating to spontaneous preterm birth.